Threshold Pharmaceuticals, Inc (THLD): Opiniones

Cuando menos te lo pienses. El producto es bueno, el partner es bueno, el acuerdo es bueno. Sólo la mala suerte daría al traste con esto.

Yo la verdad es que no me fio ni un pelo de thld,pero nada nada. hay cosas que no las veo claras y he visto muchos movimientos extraños en esta farma. No me convence demasiado. Prefiero subirme con la subida ya iniciada que pegarme otro batacazo como en amrn. Cuando atraveso como si fuera mantequilla los 4,30 me di el piro. No respeta en absoluto los soportes y si le tiene muuuucho respeto a las resistencias. Cuando paso los 6 dolares en falso me dio mucho yuyu, tardo dias en perderlos y en caer en picado. No la veo solida. No veo que haya confianza en ella. No me gustan los graficos y su linea de investigacion tiene un riesgo elevadisimo.

Gracias Solrac!

Un saludo y suerte!

Muy de acuerdo,aqui tenemos al primo de zumosol detras,,tenemos caja y no tenemos el peligro de que nos hagan la de Amrn.
Dejemosla desarrollar durante el 2014 a ver....pinta bien

En principio todo va más que bien, y los datos no son los de páncreas, así que debería tirar para arriba. Yo la tenía abandonada y precisamente estaba pensado retomarla a estos precios, pero me han tirado para atrás esas barras rojas y no voy a arriesgarme, que llevo muchos palos últimamente por no hacer caso a la tendencia. Suerte a los que estéis dentro.

Fundamentales para envidiar , tecnico para salir corriendo

Resultados buenos, aunque yo diría que bastante limitados, pero dicen que continúan con el estudio. Como tienen pasta...

Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Data to Be Presented at the 2013 WFNO/SNO Meeting

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/22/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin® (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003). No dose-limiting toxicity has been reported to date at doses of TH-302 up to 670 mg/m2 plus bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14 patients showed TH-302 in combination with bevacizumab was associated with a median time to progression of 2.8 months. One patient achieved a complete response and two patients achieved partial responses. The data will be presented this evening from 7 p.m. to 9 p.m. at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), San Francisco, CA.

Chemotherapy with radiotherapy is standard care for newly diagnosed glioblastoma. Bevacizumab is approved in the U.S. for progressive disease following prior therapy. After disease progression on bevacizumab, patients may start a subsequent bevacizumab-containing regimen. These patients typically progress in 5 to 8 weeks.1,2 Three-month progression-free survival is approximately 15%.1

"There is a critical unmet need for new medicines to treat patients with glioblastoma who experience recurrence of their disease," said Andrew J. Brenner, M.D., Ph.D., Principal Investigator of the study and Clinical Investigator with the Institute for Drug Development at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, Texas. "These preliminary data signal that TH-302 in combination with bevacizumab may have activity in patients with glioblastoma following single-agent bevacizumab failure. We are looking forward to further evaluation of TH-302 as this study continues to enroll patients."

A total of 19 patients have been enrolled in the ongoing trial. Of 14 patients evaluable for tumor response, the median time to progression was 86 days. Forty-six percent (95% CI: 18% - 74%) of patients were alive without disease progression after three months of treatment. Best tumor responses were one patient achieving a complete response, two patients achieving a partial response, and seven patients demonstrating stable disease; four patients experienced progressive disease. The longest disease stabilization is currently ongoing in one patient who achieved a partial response and is currently receiving cycle 26 at 22 months.

No grade 4 adverse events were observed at any dose. Two grade 3 adverse events were observed at 340 mg/m2 and 670 mg/m2 of skin ulceration and thrombocytopenia, respectively. The primary TH-302 related toxicities were mucosal, with rectal mucositis in two of four patients at 480 mg/m2 and four of four patients at 670 mg/m2. Limited oral mucositis was observed. Mucositis was treated conservatively and was not dose limiting.

About the Phase 1/2 Trial (Study 4003)

The ongoing phase 1/2 trial is a single-center, dose-escalation trial in patients with recurrent glioblastoma whose disease has progressed following initial combined modality treatment with radiotherapy and temozolomide and subsequent treatment with bevacizumab. The presentation at WFNO/SNO will include data from a total of 14 evaluable patients who received combination therapy of bevacizumab (10 mg/m2) and TH-302 (240 to 670 mg/m2) every two weeks. Best response was assessed by Response Assessment in Neuro-Oncology (RANO) criteria. Enrollment continues at 670 mg/m2 TH-302.

Muchas gracias por la información anaramos. Saludos.